

# Michael E Weinblatt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/103206/publications.pdf>

Version: 2024-02-01

170  
papers

19,815  
citations

20797

60  
h-index

10441

139  
g-index

185  
all docs

185  
docs citations

185  
times ranked

11770  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of Shared Epitope in Rheumatoid Arthritis Prognosis in Relation to Anti-Citrullinated Protein Antibody Positivity. <i>Rheumatology and Therapy</i> , 2022, 9, 637-647.	1.1	4
2	Screening for preclinical parenchymal lung disease in rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 3234-3245.	0.9	14
3	Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2022, 9, 391-409.	1.1	3
4	Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry. <i>Arthritis Care and Research</i> , 2021, 73, 471-480.	1.5	12
5	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. <i>Arthritis and Rheumatology</i> , 2021, 73, e1-e12.	2.9	201
6	Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR). <i>Journal of Rheumatology</i> , 2021, 48, 767-774.	1.0	33
7	Systematic review of recommendations on the use of methotrexate in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 1259-1271.	1.0	11
8	Treatment of Severe Multicentric Reticulohistiocytosis With Upadacitinib. <i>JAMA Dermatology</i> , 2021, 157, 735.	2.0	6
9	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 924-939.	1.5	466
10	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1108-1123.	2.9	339
11	Perceptions and Challenges Experienced by African Physicians When Prescribing Methotrexate for Rheumatic Disease: An Exploratory Study. <i>ACR Open Rheumatology</i> , 2021, 3, 522-530.	0.9	4
12	Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. <i>Blood Advances</i> , 2021, 5, 3445-3456.	2.5	22
13	Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies. <i>Arthritis Research and Therapy</i> , 2021, 23, 1.	1.6	41
14	Dr. Kremer et al reply. <i>Journal of Rheumatology</i> , 2021, , jrheum.210992.	1.0	0
15	Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, and Medication Change. <i>Journal of Rheumatology</i> , 2020, 47, 333-340.	1.0	5
16	Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs: Results From a Real-World Study. <i>Arthritis Care and Research</i> , 2020, 72, 176-183.	1.5	11
17	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 88-93.	0.5	63
18	Georgia Abortion Law and Our Commitment to Patients. <i>Arthritis and Rheumatology</i> , 2020, 72, 377-378.	2.9	1

#	ARTICLE	IF	CITATIONS
19	Rheumatoid arthritis-related lung disease detected on clinical chest computed tomography imaging: Prevalence, risk factors, and impact on mortality. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1216-1225.	1.6	18
20	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2. <i>Arthritis and Rheumatology</i> , 2020, 72, e1-e12.	2.9	64
21	Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 188.	1.6	2
22	The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for Achievement of Treatment Strategies. <i>Journal of Rheumatology</i> , 2020, 48, jrheum.200692.	1.0	9
23	Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center's Experience With 400 Patients. <i>ACR Open Rheumatology</i> , 2020, 2, 357-361.	0.9	43
24	Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001096.	1.8	3
25	Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2017.	1.0	0
26	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. <i>Arthritis and Rheumatology</i> , 2020, 72, 1241-1251.	2.9	142
27	Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry. <i>Clinical Rheumatology</i> , 2019, 38, 3401-3412.	1.0	11
28	The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.0	5
29	Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE). <i>Rheumatology and Therapy</i> , 2019, 6, 559-571.	1.1	15
30	Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1042-1055.	2.9	135
31	Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis. <i>Practical Laboratory Medicine</i> , 2019, 16, e00122.	0.6	2
32	Association of Changes in Anticitrullinated Protein Antibody Levels With Resource Use and Disease Activity Measures in Rheumatoid Arthritis Patients aÅUS Observational Cohort. <i>Clinical Therapeutics</i> , 2019, 41, 1057-1065.e3.	1.1	0
33	Rheumatoid Nodule Formation in the Kidney: A Diagnosis of Exclusion and a Rare Manifestation of Rheumatoid Arthritis Involving the Kidney. <i>Kidney International Reports</i> , 2019, 4, 745-748.	0.4	2
34	Prevalence and predictors for sustained remission in rheumatoid arthritis. <i>PLoS ONE</i> , 2019, 14, e0214981.	1.1	12
35	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for <i>CD40</i> and CD39. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1055-1061.	0.5	25
36	Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis. <i>BMC Rheumatology</i> , 2019, 3, 3.	0.6	18

#	ARTICLE	IF	CITATIONS
37	Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1285-1286.	0.5	5
38	Incidence and Predictors of Dyspnea on Exertion in a Prospective Cohort of Patients With Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2019, 1, 4-15.	0.9	5
39	AB0373â€¦A COMPARATIVE EFFECTIVENESS STUDY OF ABATACEPT AND TNFI AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS USING REAL-WORLD DATA. , 2019, , .		0
40	SAT0072â€¦EVALUATION OF RHEUMATOID ARTHRITIS TREATMENTS AND JOINT OUTCOMES IN RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE. , 2019, , .		0
41	FRI0171â€¦CLINICAL RESPONSES IN PATIENTS WITH INADEQUATE RESPONSE TO BDMARDS UPON TREATMENT WITH UPADACITINIB. , 2019, , .		3
42	THU0065â€¦VALIDATION OF THE ADJUSTED MULTI-BIOMARKER DISEASE ACTIVITY SCORE FOR PREDICTING RISK OF RADIOGRAPHIC PROGRESSION FOR PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
43	SAT0162â€¦A POOLED ANALYSIS OF 1-YEAR CLINICAL OUTCOMES AMONG 6-MONTH RESPONDERS AND NON-RESPONDERS FROM THREE RANDOMISED CONTROLLED STUDIES OF TNF INHIBITOR BIOSIMILARS IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
44	THU0102â€¦PATIENT DISEASE TRAJECTORIES IN BARICITINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE. , 2019, , .		0
45	Supplementing Claims Data with Electronic Medical Records to Improve Estimation and Classification of Rheumatoid Arthritis Disease Activity: A Machine Learning Approach. <i>ACR Open Rheumatology</i> , 2019, 1, 552-559.	0.9	7
46	The Impact of Exercise, Lifestyle, and Clinical Factors on Perceived Cognitive Function in Patients with Rheumatoid Arthritis: Results from a Prospective Cohort Study. <i>ACR Open Rheumatology</i> , 2019, 1, 620-626.	0.9	9
47	Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 874-883.	0.9	16
48	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 872-878.	0.5	36
49	Impact of Changes in Inflammation on Estimated Tenâ€¥ear Cardiovascular Risk in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1392-1398.	2.9	13
50	Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1419-1428.	2.9	21
51	Association of Low Bone Mineral Density with Anti-Citrullinated Protein Antibody Positivity and Disease Activity in Established Rheumatoid Arthritis: Findings from a US Observational Cohort. <i>Advances in Therapy</i> , 2018, 35, 232-242.	1.3	9
52	Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis. <i>Rheumatology and Therapy</i> , 2018, 5, 203-214.	1.1	10
53	Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 832-840.	2.9	103
54	Mavrimumab, a Fully Human Granulocyteâ€¥Macrophage Colonyâ€¥Stimulating Factor Receptor Î± Monoclonal Antibody. <i>Arthritis and Rheumatology</i> , 2018, 70, 679-689.	2.9	73

#	ARTICLE	IF	CITATIONS
55	Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids. <i>Arthritis and Rheumatology</i> , 2018, 70, 1331-1342.	2.9	15
56	Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e4-e4.	0.5	7
57	Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-severe Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 40-48.	2.9	104
58	A Randomized Phase IIb Study of Mavrimumab and Golimumab in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 49-59.	2.9	76
59	Development of abatacept- and adalimumab-specific predictive models of response to therapy in rheumatoid arthritis using data from a head-to-head study. <i>Rheumatology</i> , 2018, 57, .	0.9	0
60	Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0205013.	1.1	9
61	Phase II Study of ABT122, a Tumor Necrosis Factor and Interleukin-17A Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate. <i>Arthritis and Rheumatology</i> , 2018, 70, 1778-1789.	2.9	77
62	ABT122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate. <i>Arthritis and Rheumatology</i> , 2018, 70, 1710-1720.	2.9	55
63	Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. <i>Rheumatology</i> , 2018, 57, 1972-1981.	0.9	30
64	Methotrexate: who would have predicted its importance in rheumatoid arthritis?. <i>Arthritis Research and Therapy</i> , 2018, 20, 103.	1.6	18
65	Targeted therapies for psoriatic arthritis: an update for the dermatologist. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018, 37, 173-181.	1.6	4
66	Serum Proteomics Reveals Distinct Subtypes Associated with Treatment Response in Idiopathic Multicentric Castleman Disease. <i>Blood</i> , 2018, 132, 3716-3716.	0.6	0
67	Diet and Rheumatoid Arthritis Symptoms: Survey Results From a Rheumatoid Arthritis Registry. <i>Arthritis Care and Research</i> , 2017, 69, 1920-1925.	1.5	49
68	A randomised phase IIb study of mavrimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1020-1030.	0.5	117
69	Fibromyalgia and the Prediction of Two-Year Changes in Functional Status in Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2017, 69, 1871-1877.	1.5	12
70	Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2017, 376, 652-662.	13.9	643
71	Antimelanoma Differentiation-associated Gene 5 Dermatomyositis. <i>Journal of Rheumatology</i> , 2017, 44, 850-851.	1.0	2
72	Refractory Syndrome of Inappropriate Secretion of Antidiuretic Hormone in Systemic Lupus Erythematosus-associated Hypophysitis. <i>Journal of Rheumatology</i> , 2017, 44, 541-542.	1.0	3

#	ARTICLE	IF	CITATIONS
73	Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1853-1861.	0.5	83
74	Clinical patient registry recruitment and retention: a survey of patients in two chronic disease registries. <i>BMC Medical Research Methodology</i> , 2017, 17, 59.	1.4	7
75	Validity of the Nursesâ€™ health study physical activity questionnaire in estimating physical activity in adults with rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 234.	0.8	9
76	Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement. <i>Arthritis Research and Therapy</i> , 2017, 19, 130.	1.6	2
77	A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1937-1948.	2.9	32
78	Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities. <i>Arthritis and Rheumatology</i> , 2017, 69, 720-727.	2.9	24
79	Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration. <i>RMD Open</i> , 2016, 2, e000210.	1.8	3
80	Patientâ€™Reported Outcomes From a Twoâ€™Year Headâ€™toâ€™Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 907-913.	1.5	24
81	Efficacy and Safety of ABTâ€™494, a Selective JAKâ€™ Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. <i>Arthritis and Rheumatology</i> , 2016, 68, 2857-2866.	2.9	172
82	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. <i>Nature Communications</i> , 2016, 7, 12460.	5.8	73
83	Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia. <i>Rheumatology</i> , 2016, 55, 640-648.	0.9	29
84	Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 709-714.	0.5	134
85	Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Weekâ€™12 Efficacy and Safety Results of the Openâ€™Label Longâ€™Term Extension of a Phase III, Doubleâ€™Blind, Randomized, Placeboâ€™Controlled Trial. <i>Arthritis Care and Research</i> , 2015, 67, 1627-1636.	1.5	13
86	Editorial: The Vital Role of Randomized Controlled Trials in <i>Arthritis & Rheumatology</i>. <i>Arthritis and Rheumatology</i> , 2015, 67, 2555-2556.	2.9	1
87	Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. <i>Arthritis Research and Therapy</i> , 2015, 17, 325.	1.6	16
88	Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity. <i>Arthritis Research and Therapy</i> , 2015, 17, 343.	1.6	13
89	The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderateâ€™toâ€™Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Doubleâ€™Blind, Placebo/Activeâ€™Controlled, Doseâ€™Ranging Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 2591-2600.	2.9	86
90	The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. <i>Rheumatology</i> , 2015, 54, 2076-2084.	0.9	74



#	ARTICLE	IF	CITATIONS
91	The Association Between Reduction in Inflammation and Changes in Lipoprotein Levels and HDL Cholesterol Efflux Capacity in Rheumatoid Arthritis. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	102
92	OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2123-2129.	0.5	39
93	Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 167-173.	1.6	58
94	Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1567-1570.	0.5	31
95	An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score. <i>Arthritis Research and Therapy</i> , 2015, 17, 83.	1.6	13
96	Modular Analysis of Peripheral Blood Gene Expression in Rheumatoid Arthritis Captures Reproducible Gene Expression Changes in Tumor Necrosis Factor Responders. <i>Arthritis and Rheumatology</i> , 2015, 67, 344-351.	2.9	42
97	Clinical characteristics of RA patients with secondary SS and association with joint damage. <i>Rheumatology</i> , 2015, 54, 816-820.	0.9	41
98	Functional Impact of a Spectrum of Interstitial Lung Abnormalities in Rheumatoid Arthritis. <i>Chest</i> , 2014, 146, 41-50.	0.4	78
99	Inconsistent Treatment with Disease-modifying Antirheumatic Drugs: A Longitudinal Data Analysis. <i>Journal of Rheumatology</i> , 2014, 41, 2370-2378.	1.0	9
100	Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1â€¦.year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2152-2159.	0.5	29
101	Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. <i>Arthritis and Rheumatology</i> , 2014, 66, 3255-3264.	2.9	96
102	Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept) Tj ETQq0 0 0 rgBT /Overlock 10 Tf therapy. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1616-1625.	0.5	135
103	The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure) Tj ETQq1 1 0.7824314 rgBT /Overlock 10 Tf	1.0	14
104	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1755-1760.	0.5	11
105	The Effect of Intravenous Golimumab on Health-related Quality of Life in Rheumatoid Arthritis: 24-week Results of the Phase III GO-FURTHER Trial. <i>Journal of Rheumatology</i> , 2014, 41, 1067-1076.	1.0	14
106	A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-1± Antagonist. <i>Journal of Rheumatology</i> , 2014, 41, 2120-2128.	1.0	57
107	Serum 14-3-3± is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2104-2113.	1.0	72
108	Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 86-94.	0.5	256

#	ARTICLE	IF	CITATIONS
109	Rheumatoid arthritis quality measures and radiographic progression. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 9-13.	1.6	6
110	86.â€fHead-to-Head Comparison of Subcutaneous Abatacept Versus Adalimumab on Background Methotrexate in Rheumatoid Arthritis: Blinded Two-Year Results from the Ample Study. <i>Rheumatology</i> , 2014, 53, i88-i88.	0.9	0
111	Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1445-1452.	0.5	149
112	Headâ€toâ€head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. <i>Arthritis and Rheumatism</i> , 2013, 65, 28-38.	6.7	225
113	Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program. <i>Journal of Rheumatology</i> , 2013, 40, 787-797.	1.0	112
114	Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 381-389.	0.5	90
115	Tocilizumab as monotherapy or in combination with nonbiologic diseaseâ€modifying antirheumatic drugs: Twentyâ€fourâ€week results of an openâ€label, clinical practice study. <i>Arthritis Care and Research</i> , 2013, 65, 362-371.	1.5	56
116	Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial. <i>Journal of Rheumatology</i> , 2013, 40, 369-378.	1.0	42
117	Methotrexate in rheumatoid arthritis: a quarter century of development. <i>Transactions of the American Clinical and Climatological Association</i> , 2013, 124, 16-25.	0.9	117
118	Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. <i>Rheumatology</i> , 2012, 51, 2204-2214.	0.9	115
119	Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2011, 63, 373-382.	1.5	58
120	A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 846-854.	1.0	108
121	An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A threeâ€month randomized, placeboâ€controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. <i>Arthritis and Rheumatism</i> , 2011, 63, 337-345.	6.7	190
122	Clinical Consequences of Delayed Addition of Adalimumab to Methotrexate Therapy Over 5 Years in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 855-862.	1.0	25
123	Factors Associated with Radiographic Progression in Patients with Rheumatoid Arthritis Who Were Treated with Methotrexate. <i>Journal of Rheumatology</i> , 2011, 38, 242-246.	1.0	23
124	An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2010, 363, 1303-1312.	13.9	369
125	Case 13-2009. <i>New England Journal of Medicine</i> , 2009, 360, 1770-1779.	13.9	9
126	Methotrexate: The Foundation of Rheumatoid Arthritis Therapy. , 2009, , 307-314.		1



#	ARTICLE	IF	CITATIONS
127	Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double-blind, active drug-controlled study. <i>Arthritis and Rheumatism</i> , 2008, 58, 1921-1930.	6.7	71
128	Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2008, 58, 3309-3318.	6.7	313
129	Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. <i>Arthritis Research and Therapy</i> , 2008, 10, R95.	1.6	57
130	Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 1737-44.	1.0	27
131	Questions and answers in 2008 about biologics in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 1878-81.	1.0	0
132	RAPID: rheumatoid arthritis. <i>Journal of Family Practice</i> , 2007, 56, S1-7; quiz S8.	0.2	6
133	The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28. <i>Arthritis Research and Therapy</i> , 2006, 8, R57.	1.6	22
134	Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 228-234.	0.5	261
135	Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. <i>Journal of Rheumatology</i> , 2006, 33, 659-64.	1.0	34
136	Granulomatous lung disease occurring during etanercept treatment. <i>Arthritis and Rheumatism</i> , 2005, 53, 618-620.	6.7	70
137	Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. <i>Arthritis and Rheumatism</i> , 2005, 53, 872-878.	6.7	49
138	Rheumatoid arthritis: more aggressive approach improves outlook.. <i>Cleveland Clinic Journal of Medicine</i> , 2004, 71, 409-413.	0.6	14
139	Adalimumab, a fully human anti-tumor necrosis factor $\gamma$ monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. <i>Arthritis and Rheumatism</i> , 2003, 48, 35-45.	6.7	1,612
140	Infections and anti-tumor necrosis factor $\gamma$ therapy. <i>Arthritis and Rheumatism</i> , 2003, 48, 3013-3022.	6.7	285
141	The best of times, the worst of times: <i>Rheumatology</i> 2001. <i>Arthritis and Rheumatism</i> , 2002, 46, 567-573.	6.7	9
142	How to report radiographic data in randomized clinical trials in rheumatoid arthritis: Guidelines from a roundtable discussion. <i>Arthritis and Rheumatism</i> , 2002, 47, 215-218.	6.7	132
143	Etanercept in the treatment of adult patients with Still's disease. <i>Arthritis and Rheumatism</i> , 2002, 46, 1171-1176.	6.7	179
144	Serious liver disease in a patient receiving methotrexate and leflunomide. <i>Arthritis and Rheumatism</i> , 2000, 43, 2609-2611.	6.7	46

#	ARTICLE	IF	CITATIONS
145	Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1999, 42, 1322-1328.	6.7	248
146	A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate. <i>New England Journal of Medicine</i> , 1999, 340, 253-259.	13.9	2,044
147	Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis. A multicenter study with literature review. <i>Arthritis and Rheumatism</i> , 1997, 40, 1829-1837.	6.7	279
148	Evaluation of two interventions to reduce the ancillary costs of outpatient care for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1996, 39, 177-178.	6.7	3
149	N-[4-hydroxyphenyl] retinamide in rheumatoid arthritis: A pilot study. <i>Arthritis and Rheumatism</i> , 1996, 39, 1021-1026.	6.7	15
150	Synovial tissue response to treatment with campath-1h. <i>Arthritis and Rheumatism</i> , 1995, 38, 254-258.	6.7	50
151	American college of rheumatology preliminary definition of improvement in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995, 38, 727-735.	6.7	2,531
152	Methotrexate for Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 1994, 37, 316-328.	6.7	594
153	Lack of a renalâ€œprotective effect of misoprostol in rheumatoid arthritis patients receiving cyclosporin a. results of a randomized, placeboâ€œcontrolled trial. <i>Arthritis and Rheumatism</i> , 1994, 37, 1321-1325.	6.7	8
154	Methotrexate in rheumatoid arthritis. a five-year prospective multicenter study. <i>Arthritis and Rheumatism</i> , 1994, 37, 1492-1498.	6.7	216
155	Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1993, 36, 329-335.	6.7	187
156	The effects of drug therapy on radiographic progression of rheumatoid arthritis. results of a 36-week randomized trial comparing methotrexate and auranofin. <i>Arthritis and Rheumatism</i> , 1993, 36, 613-619.	6.7	100
157	The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. <i>Arthritis and Rheumatism</i> , 1993, 36, 729-740.	6.7	1,388
158	Long-Term Prospective Study of Methotrexate in the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 1992, 35, 129-137.	6.7	227
159	Acute and chronic suppression of leukotriene B4 synthesis EX vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. <i>Arthritis and Rheumatism</i> , 1992, 35, 376-384.	6.7	99
160	Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1990, 33, 330-338.	6.7	126
161	Inhibition of Leukotriene B <sub>4</sub> synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. <i>Arthritis and Rheumatism</i> , 1990, 33, 1149-1155.	6.7	63
162	Treatment of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1989, 2, A23-A32.	6.7	11

#	ARTICLE	IF	CITATIONS
163	Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. <i>Arthritis and Rheumatism</i> , 1989, 32, 1592-1596.	6.7	85
164	Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1988, 31, 167-175.	6.7	235
165	Cyclosporin A Treatment of Refractory Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 1987, 30, 11-17.	6.7	134
166	Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1987, 30, 988-997.	6.7	207
167	Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 39, 420-424.	2.3	7
168	Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 1985, 312, 818-822.	13.9	833
169	Chronic Monocytic Arthritis. <i>Arthritis and Rheumatism</i> , 1983, 26, 674-677.	6.7	3
170	Rheumatoid factor detection by nephelometry. <i>Arthritis and Rheumatism</i> , 1980, 23, 777-779.	6.7	21